Gastric Cancer Pipeline Insight
DelveInsight’s, “Gastric Cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Gastric Cancer Understanding
Gastric Cancer: Overview
Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It’s also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer. The most common symptoms of stomach cancer include: difficulty swallowing (dysphagia), weight loss, indigestion (dyspepsia) that doesn't go away, feeling full after eating small amounts, feeling or being sick, and tiredness due to low red blood cells (anaemia). There are different types of treatment for patients with gastric cancer. Seven types of standard treatment are used: Surgery, Endoscopic mucosal resection, Chemotherapy, Radiation therapy, Chemoradiation, Targeted therapy, and Immunotherapy.
"Gastric Cancer - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastric Cancer pipeline landscape is provided which includes the disease overview and Gastric Cancer treatment guidelines. The assessment part of the report embraces, in depth Gastric Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastric Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gastric Cancer.
Gastric Cancer Emerging Drugs Chapters
This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastric Cancer Emerging Drugs
IBI308: Innovent Biologics
IBI308 is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.
HLX10: Henlix Biotech
It is a recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection independently researched and developed by Henlius, is for the treatment of various solid tumors and can be applied in combination with other products for immuno-oncology therapy. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.
It is an investigational small molecule inhibitor of the PARP1 and PARP2 enzymes that is being evaluated as a potential monotherapy and in combination with other therapies to treat various solid tumors. Pamiparib’s early compound name was BGB-290. Currently, it is in Phase II stage of clinical trial evaluation to treat gastric cancer.
Further product details are provided in the report……..
Gastric Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Gastric Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastric Cancer
There are approx. 100+ key companies which are developing the therapies for Gastric Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.
Gastric Cancer Report Insights
- Gastric Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Gastric Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastric Cancer drugs?
- How many Gastric Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastric Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?